DMAC — DiaMedica Therapeutics Income Statement
0.000.00%
Last trade - 00:00- $340.11m
- $310.10m
- 41
- 11
- 95
- 47
Annual income statement for DiaMedica Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Total Revenue | 0 | 0 | 0 | 0 | 0 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Total Operating Expenses | 12.7 | 13.6 | 14 | 21.3 | 26.7 |
| Operating Profit | -12.7 | -13.6 | -14 | -21.3 | -26.7 |
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -12.3 | -13.6 | -13.6 | -19.3 | -24.4 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -12.3 | -13.6 | -13.7 | -19.4 | -24.4 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -12.3 | -13.6 | -13.7 | -19.4 | -24.4 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -12.3 | -13.6 | -13.7 | -19.4 | -24.4 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.784 | -0.654 | -0.517 | -0.595 | -0.605 |